ADCT
ADCT
NYSE · Biotechnology

Adc Therapeutics Sa

$1.13
+0.00 (+0.00%)
As of Aug 8, 10:21 PM ET ·
Financial Highlights (FY 2026)
Revenue
87.65M
Net Income
-153,636,249
Gross Margin
92.9%
Profit Margin
-175.3%
Rev Growth
-27.1%
D/E Ratio
3.72
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 92.9% 92.9% 56.3% 56.3%
Operating Margin -149.3% -134.4% 17.5% 15.8%
Profit Margin -175.3% -166.5% 14.9% 11.8%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 87.65M 120.21M 66.42M 54.81M
Gross Profit 81.40M 111.64M 37.41M 30.87M
Operating Income -130,889,764 -161,570,137 11.64M 8.67M
Net Income -153,636,249 -189,648,366 9.87M 6.47M
Gross Margin 92.9% 92.9% 56.3% 56.3%
Operating Margin -149.3% -134.4% 17.5% 15.8%
Profit Margin -175.3% -166.5% 14.9% 11.8%
Rev Growth -27.1% -27.1% +3.3% +12.8%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 56.63M 56.63M 206.57M 213.23M
Total Equity 15.23M 15.23M 282.56M 265.87M
D/E Ratio 3.72 3.72 0.73 0.80
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -130,119,938 -169,543,191 12.50M 10.42M
Free Cash Flow 3.90M 4.50M